Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
In a patient with colon cancer and a history of autoimmunity, skin and gastrointestinal toxicity developed after the receipt of pembrolizumab. Interleukin-17 blockade reversed the autoimmunity but led to tumor progression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“suggesting that IL-17 may have anti-tumor effects”
From The IL-17 Family of Cytokines in Health and Disease (2019) · cites this paper as Esfahani and Miller, 2017
In the citing paper
“A recent case report (Esfahani and Miller, 2017) describes a male patient with metastatic colon cancer who experienced severe flare of previously mild psoriasis following treatment with pembrolizumab (Anti-PD1).”
From The IL-17 Family of Cytokines in Health and Disease (2019) · cites this paper as Esfahani and Miller, 2017
In the citing paper
“However, there are exceptions, indicating that better understanding of the interplay between the developing antitumor response following ICI therapy and the use of immunosuppressive agents is needed (117, 122, 123).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [122]
In the citing paper
“Notably, IL-17 blockade and its probable implications in promoting tumor growth and metastasis have been reported in the literature.100,101”
From Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy (2020) · cites this paper as [101]
In the citing paper
“In this patient, several other inflammatory cytokines, mainly IL-6, TNF-α and IL-17A, were also elevated during the rejection phase, and were likely promoting the observed concomitant skin and gastrointestinal toxicities29–31.”
From Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation (2019) · cites this paper as [31]
Citations
Cites
Kryczek, I., Banerjee, M., Cheng, P., Vatan, L., Szeliga, W., Wei, S., Huang, E., Finlayson, E., Simeone, D., Welling, T. H., et al. (2009) · Blood · doi:10.1182/blood-2009-03-208249 · Cited by 813
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Johnson, D. B., Sullivan, R. J., Ott, P. A., Carlino, M. S., Khushalani, N. I., Ye, F., Guminski, A., Puzanov, I., Lawrence, D. P., Buchbinder, E. I., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4368 · Cited by 642
TH17 cells in tumour immunity and immunotherapy
Zou, W., & Restifo, N. P. (2010) · Nature Reviews Immunology · doi:10.1038/nri2742 · Cited by 624
Endogenous IL-17 contributes to reduced tumor growth and metastasis
Kryczek, I., Wei, S., Szeliga, W., Vatan, L., & Zou, W. (2009) · Blood · doi:10.1182/blood-2008-09-177360 · Cited by 403
Human T H 17 Cells Are Long-Lived Effector Memory Cells
Kryczek, I., Zhao, E., Liu, Y., Wang, Y., Vatan, L., Szeliga, W., Moyer, J., Klimczak, A., Lange, A., & Zou, W. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002949 · Cited by 278
Cited by
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Bagchi, S., Yuan, R., & Engleman, E. G. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042020-042741 · Cited by 2,189
The IL-17 Family of Cytokines in Health and Disease
McGeachy, M. J., Cua, D. J., & Gaffen, S. L. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.021 · Cited by 1,443
A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future
Esfahani, K., Roudaia, L., Buhlaiga, N., Del Rincon, S. V., Papneja, N., & Miller, W. H. (2020) · Current Oncology · doi:10.3747/co.27.5223 · Cited by 954
Self-citationThompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0013 · Cited by 570
When worlds collide: Th17 and Treg cells in cancer and autoimmunity
Knochelmann, H. M., Dwyer, C. J., Bailey, S. R., Amaya, S. M., Elston, D. M., Mazza-McCrann, J. M., & Paulos, C. M. (2018) · Cellular & Molecular Immunology · doi:10.1038/s41423-018-0004-4 · Cited by 535
Abdel-Wahab, N., Shah, M., Lopez-Olivo, M. A., & Suarez-Almazor, M. E. (2018) · Annals of Internal Medicine · doi:10.7326/m17-2073 · Cited by 487
Immune-related adverse events of immune checkpoint inhibitors: a review
Yin, Q., Wu, L., Han, L., Zheng, X., Tong, R., Li, L., Bai, L., & Bian, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1167975 · Cited by 446
Moving towards personalized treatments of immune-related adverse events
Esfahani, K., Elkrief, A., Calabrese, C., Lapointe, R., Hudson, M., Routy, B., Miller, W. H., & Calabrese, L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0352-8 · Cited by 351
Self-citationDanlos, F.-X., Voisin, A.-L., Dyevre, V., Michot, J.-M., Routier, E., Taillade, L., Champiat, S., Aspeslagh, S., Haroche, J., Albiges, L., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2017.12.008 · Cited by 300
Tison, A., Quéré, G., Misery, L., Funck‐Brentano, E., Danlos, F., Routier, E., Robert, C., Loriot, Y., Lambotte, O., Bonniaud, B., et al. (2019) · Arthritis & Rheumatology · doi:10.1002/art.41068 · Cited by 309
“Active preexisting autoimmune disease at start of ICI 37 (33) 25 (38) 12 (30) 0 (0) 0 (0) Immunosuppressants at start of ICI 24 (22) 16 (24) 5 (13) 2 (50) 1 (50) Glucocorticoids 0–15 mg/day 11 (46) 9 (56) 2 (40) 0 (0) 0 (0) Glucocorticoids 20–40 mg/day‡ 3 (13) 2 (13) 0 (0) 0 (0) 1 (100) Glucocorticoids 1–2 mg/kg/day‡…”
BackgroundInfluentialKostine, M., Finckh, A., Bingham, C. O., Visser, K., Leipe, J., Schulze-Koops, H., Choy, E. H., Benesova, K., Radstake, T. R. D. J., Cope, A. P., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217139 · Cited by 290
“172 While providing a dramatic relief of the immune-related skin, rheumatic and gastrointestinal side effects, subsequent tumour progression was observed.”
BackgroundEnterocolitis due to immune checkpoint inhibitors: a systematic review
Soularue, E., Lepage, P., Colombel, J. F., Coutzac, C., Faleck, D., Marthey, L., Collins, M., Chaput, N., Robert, C., & Carbonnel, F. (2018) · Gut · doi:10.1136/gutjnl-2018-316948 · Cited by 264
Liu, C., Liu, R., Wang, B., Lian, J., Yao, Y., Sun, H., Zhang, C., Fang, L., Guan, X., Shi, J., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001895 · Cited by 257
Rheumatic immune-related adverse events from cancer immunotherapy
Calabrese, L. H., Calabrese, C., & Cappelli, L. C. (2018) · Nature Reviews Rheumatology · doi:10.1038/s41584-018-0074-9 · Cited by 233
Haanen, J., Ernstoff, M. S., Wang, Y., Menzies, A. M., Puzanov, I., Grivas, P., Larkin, J., Peters, S., Thompson, J. A., & Obeid, M. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.285 · Cited by 222
Neurological toxicities associated with immune-checkpoint inhibitors
Touat, M., Talmasov, D., Ricard, D., & Psimaras, D. (2017) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000503 · Cited by 203
New therapeutic perspectives to manage refractory immune checkpoint-related toxicities
Martins, F., Sykiotis, G. P., Maillard, M., Fraga, M., Ribi, C., Kuntzer, T., Michielin, O., Peters, S., Coukos, G., Spertini, F., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30828-3 · Cited by 191
Muntyanu, A., Netchiporouk, E., Gerstein, W., Gniadecki, R., & Litvinov, I. V. (2021) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/1203475420943260 · Cited by 177
Development of immune checkpoint therapy for cancer
Fritz, J. M., & Lenardo, M. J. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20182395 · Cited by 175
“Suppression of T reg cells has been attempted with both anti-CD25, to starve them of their principal growth factor IL-2, or anti–CTLA-4 (Facciabene et al., 2012).”
BackgroundCook, S., Samuel, V., Meyers, D. E., Stukalin, I., Litt, I., Sangha, R., Morris, D. G., Heng, D. Y. C., Pabani, A., Dean, M., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.52302 · Cited by 167
Immune-related adverse events in various organs caused by immune checkpoint inhibitors
Okiyama, N., & Tanaka, R. (2022) · Allergology International · doi:10.1016/j.alit.2022.01.001 · Cited by 159
T helper 17 (Th17) cells and interleukin-17 (IL-17) in cancer
Chang, S. H. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01146-9 · Cited by 158
Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies
Baik, A. H., Oluwole, O. O., Johnson, D. B., Shah, N., Salem, J.-E., Tsai, K. K., & Moslehi, J. J. (2021) · Circulation Research · doi:10.1161/circresaha.120.315894 · Cited by 138
IL-17 and colorectal cancer: From carcinogenesis to treatment
Razi, S., Noveiry, B. B., Keshavarz‐Fathi, M., & Rezaei, N. (2019) · Cytokine · doi:10.1016/j.cyto.2018.12.021 · Cited by 150
On the mechanism of anti-CD39 immune checkpoint therapy
Allard, D., Allard, B., & Stagg, J. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000186 · Cited by 142
Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events
Poto, R., Troiani, T., Criscuolo, G., Marone, G., Ciardiello, F., Tocchetti, C. G., & Varricchi, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.804597 · Cited by 146
Autoimmune complications of immunotherapy: pathophysiology and management
Chan, K. K., & Bass, A. R. (2020) · BMJ · doi:10.1136/bmj.m736 · Cited by 141
Zhang, Q., Tang, L., Zhou, Y., He, W., & Li, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.663986 · Cited by 136
IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy
Johnson, D., Patel, A. B., Uemura, M. I., Trinh, V. A., Jackson, N., Zobniw, C. M., Tetzlaff, M. T., Hwu, P., Curry, J. L., & Diab, A. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0682 · Cited by 111
“Another case has been reported of a patient with pembrolizumab-induced psoriasis flare successfully treated with secukinumab, although the authors suggested that the IL17 blockade led to loss of antitumor efficacy (37).”
BackgroundFa’ak, F., Buni, M., Falohun, A., Lu, H., Song, J., Johnson, D. H., Zobniw, C. M., Trinh, V. A., Awiwi, M. O., Tahon, N. H., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006814 · Cited by 150
Esfahani, K., Al-Aubodah, T.-A., Thebault, P., Lapointe, R., Hudson, M., Johnson, N. A., Baran, D., Bhulaiga, N., Takano, T., Cailhier, J.-F., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12628-1 · Cited by 109
Self-citationPredicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines
Kang, J. H., Bluestone, J. A., & Young, A. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.02.006 · Cited by 117
Management of pulmonary toxicity associated with immune checkpoint inhibitors
Delaunay, M., Prévôt, G., Collot, S., Guilleminault, L., Didier, A. P., & Mazières, J. (2019) · European Respiratory Review · doi:10.1183/16000617.0012-2019 · Cited by 114
Effects of immune‐related adverse events ( irAEs ) and their treatment on antitumor immune responses
Blum, S. M., Rouhani, S. J., & Sullivan, R. J. (2023) · Immunological Reviews · doi:10.1111/imr.13262 · Cited by 115
Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events
Les, I., Martínez, M., Pérez-Francisco, I., Cabero, M., Teijeira, L., Arrazubi, V., Torrego, N., Campillo-Calatayud, A., Elejalde, I., Kochan, G., et al. (2023) · Cancers · doi:10.3390/cancers15051629 · Cited by 100
Lee, D. J., Lee, H. J., Farmer, J. R., & Reynolds, K. L. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01530-2 · Cited by 108
Crossed Pathways for Radiation-Induced and Immunotherapy-Related Lung Injury
Zhang, Z., Zhou, J., Verma, V., Liu, X., Wu, M., Yu, J., & Chen, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.774807 · Cited by 110
Nikolaou, V. A., Sibaud, V., Fattore, D., Sollena, P., Ortiz‐Brugués, A., Giacchero, D., Romano, M. C., Riganti, J., Lallas, K., Peris, K., et al. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.08.137 · Cited by 101
Campochiaro, C., Farina, N., Tomelleri, A., Ferrara, R., Lazzari, C., Luca, G. D. D., Bulotta, A., Signorelli, D., Palmisano, A., Vignale, D., et al. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.07.016 · Cited by 99
Feng, W., Zhang, Y., Xu, Z., Yu, S.-Y., Huo, J., Tuersun, A., Zheng, M., Zhao, J., Zong, Y., & Lu, A. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04187-3 · Cited by 103
“Unfortunately, progression of colon cancer occurred after anti-IL-17 treatment was given to treat the psoriasis flare [12], supporting a role for IL-17A in antitumour immunity.”
BackgroundBass, A. R., Abdel‐Wahab, N., Reid, P. D., Sparks, J. A., Calabrese, C. M., Jannat‐Khah, D., Ghosh, N., Rajesh, D., Aude, C. A., Gedmintas, L., et al. (2023) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2023-223885 · Cited by 98
Roberts, J., Ennis, D., Hudson, M., Ye, C., Saltman, A., Himmel, M. E., Rottapel, R. K., Pope, J. E., Hoa, S. A.-T., Tisseverasinghe, A., et al. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102595 · Cited by 82
Anderson, R., Theron, A. J., & Rapoport, B. L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02254 · Cited by 77
Adverse events induced by immune checkpoint inhibitors
Perdigoto, A. L., Kluger, H. M., & Herold, K. C. (2021) · Current Opinion in Immunology · doi:10.1016/j.coi.2021.02.002 · Cited by 83
“Secukinumab IL-17A mAb • Psoriatic rash and colitis [88] • Psoriasiform dermatological complication [89] Tumor progression occurred in one patient [88] but in the other there was no impact on tumor response [89].”
BackgroundImmune Checkpoint Inhibitor–Mediated Diarrhea and Colitis: A Clinical Review
Gong, Z., & Wang, Y. (2020) · JCO Oncology Practice · doi:10.1200/op.20.00002 · Cited by 75
Roberts, J., Smylie, M., Walker, J. W. T., Basappa, N. S., Chu, Q. S.-C., Kolinsky, M. P., Lyddell, C., & Ye, C. (2019) · Clinical Rheumatology · doi:10.1007/s10067-019-04451-2 · Cited by 75
“While TNFi are generally considered safe in the short term and are commonly used in the treatment of ICI-induced colitis, a recent case report described loss of tumor response after use of an IL-17 inhibitor [20].”
BackgroundHoa, S. A.-T., Laaouad, L., Roberts, J., Ennis, D., Ye, C., Jumaily, K. A., Pope, J. E., Nevskaya, T., Saltman, A., Himmel, M. E., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02851-5 · Cited by 70
Adverse events associated with immune checkpoint inhibitor treatment for cancer
Esfahani, K., Meti, N., Miller, W. H., & Hudson, M. (2019) · Canadian Medical Association Journal · doi:10.1503/cmaj.180870 · Cited by 65
Self-citationThe role of interleukin-17 in inflammation-related cancers
Zhang, X., Li, B., Lan, T., Chiari, C. C., Ye, X., Wang, K., & Chen, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1479505 · Cited by 89
Th17 cell function in cancers: immunosuppressive agents or anti-tumor allies?
Taghizadeh-Anvar, M., Rashidan, K., Arsam, N., Rasouli‐Saravani, A., Yadegari, H., Ahmadi, A., Asgari, Z., Vanan, A. G., Ghorbaninezhad, F., & Tahmasebi, S. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03525-9 · Cited by 78
“Contrarily, researchers found that exposing breast cancer cell lines to IL-17E had an anti-tumorigenesis impact [204].”
BackgroundHu, X., Majchrzak, K., Liu, X., Wyatt, M. M., Spooner, C. J., Moisan, J., Zou, W., Carter, L., & Paulos, C. M. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3973 · Cited by 64
“Interestingly, a recent report indicates that treatment of anti-PD1-induced autoimmune toxicity by anti-IL-17A secukinumab resulted in loss of anti-tumor activity in a metastatic colon cancer patient (8).”
BackgroundPD-1 and TIM-3 differentially regulate subsets of mouse IL-17A–producing γδ T cells
Edwards, S. C., Hedley, A., Hoevenaar, W. H. M., Wiesheu, R., Glauner, T. A., Kilbey, A., Shaw, R., Boufea, K., Batada, N. N., Hatano, S., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20211431 · Cited by 60
“Anti–PD-1 immunotherapy, although effective against some melanomas, can also exacerbate psoriasis and colitis (Tanaka et al., 2017), but IL-17A blockade may reverse these toxicities (Esfahani and Miller, 2017; Johnson et al., 2019).”
BackgroundKim, K. H., Hur, J. Y., Cho, J., Ku, B. M., Koh, J., Koh, J., Sun, J., Lee, S., Ahn, J. S., Park, K., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1722023 · Cited by 69
“Intriguingly, IL-17A blocking antibody was also tried in the management anti-PD-1-induced irAEs.(24,25) In the TNF-related subgroup, the percentage of TNF-α cells among the CD4 and CD8 T cell populations was typically high Figure 3.”
BackgroundMicrobiota-Propelled T Helper 17 Cells in Inflammatory Diseases and Cancer
Bellone, M., Brevi, A., & Huber, S. (2020) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00064-19 · Cited by 65
Peripheral nervous system immune-related adverse events due to checkpoint inhibition
O’Hare, M., & Guidon, A. C. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-01001-6 · Cited by 66
“Case reports have described successful use of the IL-17 inhibitor sekunimab in the management of gastrointestinal and dermatological irAEs due to checkpoint inhibition 124,125 .”
IL-17A promotes tumorigenesis and upregulates PD-L1 expression in non-small cell lung cancer
Liao, H., Chang, X., Gao, L., Ye, C., Qiao, Y., Xie, L., Lin, J., Cai, S., & Dong, H. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04365-3 · Cited by 55
“The cancer progressed after administration of secukinumab (a human circulating interleukin-17A monoclonal antibody) for psoriasis while continuing to receive pembrolizumab for another two cycles [43].”
BackgroundExpert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications
Cappelli, L. C., & Bingham, C. O. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41587 · Cited by 53
“There is a case report of tumor progression with secukinumab when used for psoriasis (49), while another case of pembrolizumab-induced psoriasis was treated successfully in this way without progression (50).”
BackgroundCytokine dynamics and targeted immunotherapies in autoimmune encephalitis
Ciano-Petersen, N. L., Muñiz‐Castrillo, S., Birzu, C., Vogrig, A., Farina, A., Villagrán‐García, M., Joubert, B., Psimaras, D., & Honnorat, J. (2022) · Brain Communications · doi:10.1093/braincomms/fcac196 · Cited by 58
“vel anti-IL17A therapies such as ixekizumab and brodalumab could also be proposed to antagonize this pathway, although the use of anti-IL17A therapies in paraneoplastic cases should be carefully considered until further studies clarifies its impact on anti-tumour immune response.(132)”
BackgroundPan, Y., Yang, W., Tang, B., Wang, X., Zhang, Q., Li, W., & Li, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1192303 · Cited by 59
“Although IL-17 blockade improved psoriasis symptoms and gastrointestinal pain, antitumor activity decreased as serum CEA returned to pre-treatment levels (164).”
BackgroundIL-36 family cytokines in protective versus destructive inflammation
Han, Y., Huard, A., Mora, J., da Silva, P., Brüne, B., & Weigert, A. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109773 · Cited by 52
Berg, M. H., Rincon, S. V. D., & Miller, W. H. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003551 · Cited by 58
Self-citationGuo, X., Chen, S., Wang, X., & Liu, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1138483 · Cited by 57
“There have been cases of effective use of the anti-IL-17 monoclonal antibody secukinumab in the treatment of intestinal and cutaneous iRAEs, although it may promote tumor immune escape (101).”
BackgroundCoureau, M., Meert, A., Berghmans, T., & Grigoriu, B. D. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00137 · Cited by 48
“Esfahani K, Miller WH Jr. Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade.”
BackgroundTargeting molecular pathways to control immune checkpoint inhibitor toxicities
Reschke, R., Sullivan, R. J., Lipson, E. J., Enk, A. H., Gajewski, T. F., & Hassel, J. C. (2024) · Trends in Immunology · doi:10.1016/j.it.2024.11.014 · Cited by 50
Rheumatic Immune-Related Adverse Events due to Immune Checkpoint Inhibitors—A 2023 Update
Dang, Q. M., Watanabe, R., Shiomi, M., Fukumoto, K., Nobashi, T. W., Okano, T., Yamada, S., & Hashimoto, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065643 · Cited by 54
“This provides the rationale for targeted inhibition of these cytokines to treat rheumatic irAEs [65,66].”
BackgroundImproving safety of cancer immunotherapy via delivery technology
Hu, D., Zhang, W., Tang, J., Zhou, Z., Liu, X., & Shen, Y. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120407 · Cited by 47
Calabrese, L. H., & Mariette, X. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-212061 · Cited by 44
Management of rheumatic complications of ICI therapy: a rheumatology viewpoint
Leipe, J., & Mariette, X. (2019) · Rheumatology · doi:10.1093/rheumatology/kez360 · Cited by 48
Zhang, L., Zhang, M., Jin-xiu, X., Li, S., Chen, Y., Wang, W., Yang, J., Li, S., & Gu, M. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-6719 · Cited by 43
“Recent studies have shown that IL-17 and Th17 cells may play an important role in the efficacy and toxicity of checkpoint-blocking therapy in cancer patients (82).”
ResultGeorge, S., Bell, E. J., Zheng, Y., Kim, R., White, J. C., Devgan, G., Smith, J., Lal, L. S., Engel-Nitz, N. M., & Liu, F. X. (2021) · The Oncologist · doi:10.1002/onco.13812 · Cited by 44
“The exact pathophysiology of immune-related adverse events (irAEs) remains unknown, but evidence suggests they may result from a combination of autoreactive T cells, autoantibodies, and proinflammatory cytokines [11, 12].”
Management of Brain Metastases in the New Era of Checkpoint Inhibition
Lauko, A. J., Thapa, B., Venur, V. A., & Ahluwalia, M. S. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0877-8 · Cited by 42
A Review of Immune-Mediated Adverse Events in Melanoma
Kennedy, L. B., & Salama, A. K. S. (2019) · Oncology and Therapy · doi:10.1007/s40487-019-0096-8 · Cited by 43
“research suggests that irAEs develop through a combination of pathways involving autoreactive T cells, autoantibodies, and cytokines [6, 7].”
BackgroundQiu, W., Wang, B., Gao, Y., Tian, Y., Tian, M., Chen, Y., Xu, L. M., Yao, T., Li, P., & Yang, P. (2019) · Hepatology · doi:10.1002/hep.30960 · Cited by 40
Mechanistic insights into cancer immunity and immunotherapy
Zou, W. (2018) · Cellular and Molecular Immunology · doi:10.1038/s41423-018-0011-5 · Cited by 59
Katsume, Y., Isawa, T., Toi, Y., Fukuda, R., Kondo, Y., Sugawara, S., & Ootomo, T. (2018) · Internal Medicine · doi:10.2169/internalmedicine.0255-17 · Cited by 40
“The precise pathophysiology of irAEs remains unknown; however, several studies have shown that T-cells, antibodies, and the cytokine response may be associated with irAEs (6, 7).”
BackgroundPeripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy
Kim, K. H., Kim, C. G., & Shin, E. (2020) · Immune Network · doi:10.4110/in.2020.20.e8 · Cited by 39
“Interestingly, IL-17A blockade can successfully treat irAEs induced by anti-PD-1 therapy (67,68).”
BackgroundRapoport, B. L., Shannon, V. R., Cooksley, T., Johnson, D. B., Anderson, L., Blidner, A. G., Tintinger, G. R., & Anderson, R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.743582 · Cited by 44
Translation of cancer immunotherapy from the bench to the bedside
Guo, Q., Huang, F., Gonçalves, C., Rincon, S. V. D., & Miller, W. H. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.001 · Cited by 43
Self-citationAdvances on immune-related adverse events associated with immune checkpoint inhibitors
Fan, Y., Geng, Y., Shen, L., & Zhang, Z. (2020) · Frontiers of Medicine · doi:10.1007/s11684-019-0735-3 · Cited by 37
“A case report published in the New England Journal of Medicine also demonstrated that interleukin-17 blockade dramatically decreased the antitumor efficacy of pembrolizumab in a patient with metastatic colon cancer [58].”
BackgroundHLA and tumour immunology: immune escape, immunotherapy and immune-related adverse events
Jiang, N., Yu, Y., Wu, D., Wang, S., Fang, Y., Miao, H., Ma, P., Huang, H., Zhang, M., Zhang, Y. X., et al. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04493-1 · Cited by 41
“Proinflammatory cytokines, including IL-17, also play an important role in the occurrence and development of irAEs (Esfahani and Miller 2017).”
BackgroundImmune Checkpoint Inhibitors in Breast Cancer: A Narrative Review
Filho, P. N., Albuquerque, C., Capella, M. P., & Debiasi, M. (2023) · Oncology and Therapy · doi:10.1007/s40487-023-00224-9 · Cited by 44
A drug safety evaluation of risankizumab for psoriasis
Huang, Y., & Tsai, T. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1736034 · Cited by 34
“The risk of malignancy of risankizumab seems to be comparable to placebo, but loss of tumor response have been observed after IL-17 blockade [53].”
BackgroundMurray‐Brown, W., Wilsdon, T. D., Weedon, H., Proudman, S., Sukumaran, S., Klebe, S., Walker, J. G., Smith, M., & Wechalekar, M. D. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000281 · Cited by 39
Kao, C., Charmsaz, S., Alden, S. L., Brancati, M., Li, H. L., Balaji, A., Munjal, K., Howe, K., Mitchell, S., Leatherman, J. M., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci176567 · Cited by 36
“Inhibition of the IL-17 pathway with secukinumab for the treatment of irAEs was associated with tumor progression in a single patient report, but other reports indicated successful irAE treatment without concurrent tumor growth (81, 84).”
Association of Chronic Immune-Mediated Diarrhea and Colitis With Favorable Cancer Response
Zou, F., Abu‐Sbeih, H., Ma, W., Peng, Y., Qiao, W., Wang, J., Shah, A. Y., Oliva, I. C. G., Piha-Paul, S. A., Thompson, J. A., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7647 · Cited by 31
“Melanoma 20 (23) 12 (28) 8 (18) Head and neck 9 (10) 4 (9) 3 (7)”
Li, B., Jiang, C., Pang, L., Zou, B., Ding, M., Sun, X., Yu, J., & Wang, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.627197 · Cited by 32
“This results in an immuneboosting effect through a series of processes involving autoreactive lymphocytes, autoantibodies, and cytokines (37, 38).”
BackgroundChallenge of Rechallenge: When to Resume Immunotherapy Following an Immune-Related Adverse Event
Nakajima, E. C., Lipson, E. J., & Brahmer, J. R. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01623 · Cited by 28
Bouhlel, L., Doyen, J., Chamorey, E., Poudenx, M., Ilié, M., Gal, J., Guigay, J., Benzaquen, J., Marquette, C., Berthet, J., et al. (2020) · Bulletin du Cancer · doi:10.1016/j.bulcan.2020.04.019 · Cited by 26
Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy
Shen, P., Deng, X., Hu, Z., Chen, Z., Huang, Y., Wang, X., Qin, K., Huang, Y., Ba, X., Yan, J., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.762247 · Cited by 28
Kubo, T., Hirohashi, Y., Tsukahara, T., Kanaseki, T., Murata, K., Morita, R., & Torigoe, T. (2021) · Immunological Medicine · doi:10.1080/25785826.2021.1976942 · Cited by 26
Large Granular Lymphocytic Leukemia: From Immunopathogenesis to Treatment of Refractory Disease
Zawit, M., Bahaj, W., Gurnari, C., & Maciejewski, J. P. (2021) · Cancers · doi:10.3390/cancers13174418 · Cited by 25
Immune-mediated colitis after immune checkpoint inhibitor therapy
Giesler, S., Riemer, R., Lowinus, T., & Zeiser, R. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.09.009 · Cited by 29
Denk, D., Ramakrishnan, M., Conche, C., Pallangyo, C. K., Pesic, M. H., Ceteci, F., Kennel, K. B., Kirisözü, A. C., Engel, E., Mohs, K., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.02.005 · Cited by 25
Cao, T., Zhou, X., Wu, X., & Zou, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1207544 · Cited by 27
“Since the suppressive effects of checkpoints on the immune response are inhibited by ICIs, lymphocytes become overactivated (22, 23), pro-inflammatory cytokines are abundantly released (24, 25), and immune tolerance is destroyed (26, 27), all of which may contribute to the irAEs.”
BackgroundT cell-mediated mechanisms of immune-related adverse events induced by immune checkpoint inhibitors
Li, L., Huang, Y., Xue, R., Li, L., Li, L., Liang, L., Lai, K., Huang, X., Qin, Y., & Zheng, Y. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104808 · Cited by 28
Hatano, R., Itoh, T., Otsuka, H., Okamoto, S., Komiya, E., Iwata, S., Aune, T. M., Dang, N. H., Kuwahara‐Arai, K., Ohnuma, K., et al. (2019) · mAbs · doi:10.1080/19420862.2019.1654305 · Cited by 23
“As expected, cases of adverse effects of IL-17-targeting therapy for psoriasis involving neutropenia and fungal infection, especially Candida infection, have been reported.(38,39) Our study showed that anti-IL-26 mAb markedly suppressed the pathognomonic symptoms of angiogenesis and infiltration of inflammatory cells…”
BackgroundImmune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Therapy
Ho, A. K., Ho, A. M. ‐., Cooksley, T., Nguyen, G., Erb, J., & Mizubuti, G. B. (2020) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000005029 · Cited by 24
Gérard, A. O., Doyen, J., Crémoni, M., Bailly, L., Zorzi, K., Ruetsch-Chelli, C., Brglez, V., Picard‐Gauci, A., Troin, L., Esnault, V. L. M., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002512 · Cited by 25
Sakai, K., Sakurai, T., Velasco, M. A. D., Nagai, T., Chikugo, T., Ueshima, K., Kura, Y., Takahama, T., Hayashi, H., Nakagawa, K., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.763468 · Cited by 24
“ICIs may sway this balance in favor of an increased TH17 cell response with robust IL-17 secretion and away from Treg-mediated self-tolerance, which has been hypothesized to contribute to ICI-induced colitis (19).”
Background
Metadata
- Authors
- Esfahani, K., & Miller, W. H.
- Affiliations
- McGill University (CA)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-05-18
- Volume
- 376
- Issue
- 20
- Pages
- 1989-1991
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2615312978
- Cited by
- 200
- References
- 5
- Citations by year
- 2026: 10 · 2025: 18 · 2024: 27 · 2023: 22 · 2022: 14 · 2021: 30 · 2020: 33 · 2019: 28 · 2018: 15 · 2017: 3
- FWCI
- 9.53
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- pembrolizumab, immune checkpoint inhibitor toxicity, autoimmune toxicity, colon cancer, tumor progression, immune-related adverse events
- MeSH terms
- Antibodies, Monoclonal, Autoimmune Diseases, Colonic Neoplasms, Crohn Disease, Exanthema, Humans, Male, Middle Aged, Interleukin-17, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.